ClinicalTrials.gg
CompletedNCT05982483Updated Aug 8, 2023

Erector Spinae Plane Block vs. Usual Care for ED Patients With Mechanical Back Pain

An interventional study of Erector Spinae plane block using 20 ml of bupivicaine 0.25% and Usual care in Back Pain, sponsored by Island Health. Completed at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-08-08.

Sponsored by Island Health · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 3 years 9 months after the study started (first participant enrolled Sep 2019, registered Jul 2023).
Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to compare the Erector Spinae plane (ESP) block, a nerve block, to usual care in emergency department patients with back pain. The main question it aims to answer:

Is the ESP block superior to usual care in the treatment of back pain in the emergency department? Participants will be randomly assigned to the ESP or the usual care group. Pain improvement at the time of emergency department discharge will be compared.

02

Conditions studied

  • Back Pain

Keywords

  • nerve block
  • back pain
  • regional anaesthesia
  • analgesia
03

In context

Back Pain

2,389 studies on the registry are indexed under Back Pain; 282 are open to participants now.

This study's enrollment of 30 is below the median of 60 across 1,952 interventional studies indexed under Back Pain.

Browse Back Pain studies →

Lead sponsor

This is the only study on the registry with Island Health as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: Patients deemed to have mechanical back pain with a component of paravertebral tenderness or paravertebral spasm reported by the patient or noted on examination by treating physician.

Exclusion Criteria:

  • previous recipient of erector spinae plane block
  • exam concerning for cauda equina syndrome
  • current IV drug use
  • organ transplant recipient
  • history of or suspected bleeding diathesis
  • current use of anticoagulants
  • sepsis or soft tissue infection at site of the block within last three months
  • pregnancy
  • overt malignancy involving skin or underlying soft tissue at the site of block
  • allergy to any of the research medications
  • inability to participate in telephone follow-up
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Care provider, Outcomes assessor)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    ESP cohort

    Randomized to receive the ultrasound-guided ESP block.

    Procedure: Erector Spinae plane block using 20 ml of bupivicaine 0.25%

  • Active comparator
    Usual care cohort

    Randomized to usual care as dictated by the treating emergency physician

    Drug: Usual care

Interventions

  • ProcedureErector Spinae plane block using 20 ml of bupivicaine 0.25%

    Utilizing the in line approach, a 22 gauge 3.5" spinal needle was guided the the tip of the transverse process corresponding to the area of maximal tenderness or central to the reported area of spasm. 1% lidocaine with epinephrine was used for skin anaesthesia and for hydro-localization of the needle tip on approach to the tip of the transverse process. Once the needle tip made contact with the transverse process, 2-3 ml of 1% lidocaine with epinephrine was injected to open the ESP plane. If there was no reported tachycardia after approximately 45 seconds, 20 ml of 0.25% bupivicaine was injected into the ESP plane.

  • DrugUsual care

    Analgesia as dictated by the treating emergency physician

06

What researchers measure

Primary outcomes

  1. Numeric Verbal Pain Score (NVPS) reduction at emergency department discharge

    The NVPS is an 11-point verbal pain scale from 0 to 10 with 0 representing no pain and 10 the worst pain imaginable.

    Time frame: Numeric verbal pain score (NVPS) at time of randomization compared with NVPS at time of discharge from the emergency department up to 24 hours after randomization.

Secondary outcomes

  1. Number of patients requiring post randomization Emergency department (ED) opiate analgesia analgesia use

    Opiate medication dose and route of administration was recorded

    Time frame: Time of randomization to time of ED discharge up to 24 hours after randomization.

  2. Emergency department (ED) length of stay.

    Time spent in the emergency department.

    Time frame: Time of ED triage to time of ED discharge up to 24 hours after triage.

  3. Brief Pain Inventory (BPI) score reduction from baseline

    The Brief Pain Inventory (BPI) is widely used to measure a patients' pain intensity and interference the pain has on daily function measured in 7 categories: mood, work, general activity, walking, relationships, enjoyment of life, and sleep. The patient rates each of these on a scale from 0-10with 0 representing no interference and 10 complete interference in that aspect of life. The initial BPI was recorded at time of randomization and subsequent BPI's recorded by telephone follow-up at predetermined time intervals

    Time frame: Time of randomization compared to 1 day, 1 week, 1 month, and 3 months post Emergency department visit

  4. Number of patients requiring post Emergency department discharge opiate analgesia use

    During telephone follow up, patients were asked if there was any opiate analgesia used during the pre-determined time period.

    Time frame: Date of randomization to 1 day after randomization, 1 day after randomization to 1 week after randomization, 1week after randomization to 1 month after randomization, 1 month after randomization to 3 months after randomization.

  5. Post Emergency department (ED) discharge Numeric Verbal Pain Score (NVPS)

    At telephone follow up at predetermined time intervals, patients were asked what their most severe level of pain they were currently experiencing as measured by the NVPS

    Time frame: 1 day after randomization, 1 week after randomization, 1 month after randomization, 3 months after randomization.

  6. Number of patients able to ambulate post ED treatment if unable to on ED admission

    If patient was unable to ambulate on ED admission, did ED treatment allow ambulation without assistance: yes or no

    Time frame: Time of ED triage compared to time of ED discharge up to 24 hours after triage.

  7. Number of patients requiring Emergency department (ED) return visits for back pain

    At telephone follow up at predetermined intervals, patients were asked if they had to return subsequently to the emergency department due to their back pain

    Time frame: Date of randomization to 1 day after randomization, 1 day after randomization to 1 week after randomization, 1week after randomization to 1 month after randomization, 1 month after randomization to 3 months after randomization.

07

Study locations

1 site
  • Nanaimo Regional General Hospital
    Nanaimo, British Columbia V9S2B7, Canada
08

References and documents

Publications

  • Ho B, Fyfe-Brown R, Chopra S, McMeel K. The erector spinae plane block vs. usual care for treatment of mechanical back pain in the emergency department: a pilot study. CJEM. 2024 Aug;26(8):543-548. doi: 10.1007/s43678-024-00748-7. Epub 2024 Jul 31. PubMed 39083200 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 8, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05982483
Lead sponsor
Island Health
Responsible party
Ben Ho (Emergency department staff physician, Island Health) — Principal investigator
First posted
Aug 8, 2023
Start date
Sep 8, 2019
Primary completion
Jan 16, 2023
Completion
Jan 16, 2023
Last update
Aug 8, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion